sGC

Decisions regarding caplacizumab and eculizumab are complex, and include considerations over costs, side effects, and efficacy. ADAMTS13 (congenital TTP or Upshaw-Schulman Syndrome), compliment mediated TMA (atypical hemolytic uremic syndrome, aHUS),…